35,700 new cases of multiple myeloma are diagnosed each year. In the US, the average lifetime risk of being diagnosed with MM is 1 in 103 for men and 1 in 131 for women. The average age of people diagnosed is 69. #MyelomaActionMonth #MyelomaMilestone #RaiseAwareness

Multiple myeloma is the second most common blood cancer after lymphoma and accounts for about 2% of all cancers diagnosed in the United States. #MyelomaActionMonth #MyelomaMilestone #RaiseAwareness

Multiple myeloma is a type of blood cancer that often goes undiagnosed in its early stages. Being aware of the warning signs can help catch the disease sooner which could improve treatment outcomes. 🔍 #MultipleMyeloma #EarlyDetection #KnowTheSigns #MyelomaActionMonth

The MM incidence rate is notably higher in people of African descent and is the most common hematologic malignancy in this population. Source: pmc.ncbi.nlm.nih.gov/articles/PMC30…

What’s the Difference? 🧐 Though their names sound similar, myeloma and melanoma are different types of cancer. 🔹 Myeloma is a cancer of the plasma cells that affects the blood. 🔹 Melanoma is a cancer of the melanocytes, the cells responsible for producing pigment in the skin.

The average lifetime risk of being diagnosed with multiple myeloma is about 1 in 103 for men and about 1 in 131 for women. #MyelomaActionMonth #RaiseAwareness

Starton will have a poster presentation at this year's AACR Annual Meeting on April 28, 2025 #AACR25 startontx.com/2025/03/26/sta…

Multiple myeloma may present significant challenges, and patients battling this cancer show incredible strength and resilience throughout their journey. Sharing and raising awareness helps others understand the disease. #MyelomaActionMonth #MyelomaMilestone #RaiseAwareness

A relative survival rate compares people with the same type and stage of cancer to people in the overall population. The 5-year relative survival rate for multiple myeloma is 61%. #MyelomaActionMonth #MyelomaMilestone #RaiseAwareness

Visit our new website! At Starton, we’re focused on transforming therapies with proprietary continuous delivery technology, so people with #cancer live better, for longer. Learn more about our approach and progress here: startontx.com

Our mission is to develop therapies that address unmet needs with precision-based drug delivery solutions.

We’re excited to present positive data from our Phase 1b trial demonstrating the potential of our lead candidate STAR-LLD in relapsed/refractory multiple myeloma at #AACR25. Learn more about the results here: startontx.com/starton-therap…

As we observe National Cancer Research Month this May, we reaffirm our unwavering commitment to advancing the field of oncology and improving the lives of patients affected by MM and CLL. #CancerResearchMonth #ResearchSavesLives

Oncology nurses play a critical role in their patients’ cancer journey. We thank you for your dedication and passion for helping those in need! #OncologyNursingMonth

Our CEO recently presented a corporate overview at the Centri Capital Conference discussing how we are transforming standard-of-care therapies with our proprietary continuous delivery technology to deliver superior outcomes. Learn about our approach here: startontx.com

ICYMI we presented new clinical data at #AACR25 from our Phase 1b study, showcasing how continuous delivery technology could potentially demonstrate superiority in efficacy and tolerability compared to Revlimid. Learn more about the results here: startontx.com/starton-therap…

James Lind conducted the first randomized clinical trial today in 1747. He tested different treatments for scurvy among sailors, discovering that citrus fruits were effective in preventing scurvy. Supporting clinical trials brings us one step closer to better health for all!

Sunday is #NationalCancerSurvivorsDay, we honor the strength, courage, and resilience of those who face cancer. At Starton, we're advancing innovative solutions to potentially improve outcomes and quality of life. Here's to life, hope, and perseverance. #CancerAwareness

We’re pleased to share that our Phase 2a clinical trial evaluating STAR-LLD in patients with multiple myeloma is now open for enrollment. This is an important step forward in our mission to develop innovative therapies for patients. Read more here: startontx.com/starton-therap…

“We are excited to enter into this agreement with Bend Bioscience for the development of an oral sustained release formulation of STAR-LLD” said Pedro Lichtinger, Starton Therapeutics Chairman and CEO. Read more here: startontx.com/starton-therap…